Abbvie Inc (ABBV-N) Quote - Press Release (2024)

Motley Fool - Sat Apr 20, 2:44AM CDT

My top financial goal is to grow my passive income so that it can eventually cover my monthly expenses. I've made a variety of passive income investments, including dividend stocks, real estate partnerships, and bonds. One of my favorite vehicles for generating passive income is investing in exchange-traded funds (ETFs).

I own several income-focused ETFs, including the JPMorgan Equity Premium Income ETF(NYSEMKT: JEPI). I routinely buy more shares of the ETF, which offers a lucrative monthly income stream. Here's why it's one of my favorite ETFs for passive income.

A premium passive income producer

The JPMorgan Equity Premium Income ETF is an actively managed fund. Its primary goal is to deliver monthly income and equity market exposure with less volatility than the broader stock market. The ETF has certainly lived up to its name over the past year, delivering premium income compared to other yield-focused asset classes.

As that chart shows, it has delivered nearly as much income as the average U.S. high-yield bond over the past 30 days. Meanwhile, its yield is even higher over the past 12 months at 8.5%. That's more than double the income yield of a 10-year treasury or real estate investment trust (REIT).

The fund makes monthly distribution payments to investors. One caveat is that those payments can vary considerably from month to month.

Abbvie Inc (ABBV-N) Quote - Press Release (2)

JEPI Dividend data by YCharts

However, the overall annual yield has been very attractive since the fund's inception.

Even though it's an actively managed fund, it has a very reasonable ETF expense ratio of 0.35%. That low cost enables investors to keep more of the income the ETF generates on their behalf.

How the fund produces premium income

The JPMorgan Equity Premium ETF has a two-pronged strategy to generate income for fund investors:

  • A defensive equity portfolio: The fund's managers use a bottom-up fundamental research process to select high-quality stocks based on its proprietary risk-adjusted stock ranking. Many of these stocks supply dividend income.
  • A disciplined options overlay strategy: The fund's managers write out-of-the-money call options on the S&P 500 Index to generate monthly distributable income.

The fund's defensive equity portfolio currently has more than 100 holdings, led by:

  • Progressive: The insurance company made up 1.7% of the fund's net assets. It pays a 0.5%-yielding dividend.
  • Trane Technologies: The HVAC manufacturing company comprised 1.7% of the fund's assets. It currently pays a dividend yielding 1.1%.
  • Microsoft Corporation: The technology titan made up 1.7% of the portfolio. It pays a 0.7% dividend.
  • Amazon: The e-commerce giant comprised 1.7% of the fund's net assets. It doesn't currently pay a dividend.
  • Meta Platforms: The social media behemoth comprised 1.6% of the fund's holdings. It recently initiated a dividend and currently yields 0.4%.

The fund also holds a few higher-yielding dividend stocks, including top-10 holdings ExxonMobil (3.2%) and AbbVie (3.8%). These holdings provide the fund with dividend income and price appreciation potential.

The other piece of its portfolio is out-of-the-money call options written on the S&P 500. These options generate premium income as they expire each month, which the fund distributes to investors. Option premiums are higher when volatility spikes, so the fund can generate more call option premium income during periods of market volatility. That also helps offset the equity portfolio's volatility.

The fund aims to outperform the S&P 500 total return index by delivering high income returns from the monthly cash distributions and solid value appreciation as the stocks in the portfolio rise. It also aims to achieve those returns with less volatility than the broader market.

An excellent ETF for passive income

The JPMorgan Equity Premium Income ETF has done an excellent job delivering a premium passive income stream to fund investors. While the monthly payment ebbs and flows with the income generated by options and dividends, it has produced a higher yield than most income-focused investments over the past year. Furthermore, it does that while reducing risk and volatility. Those features make it an excellent addition to my passive income portfolio, which is why I keep buying shares of this high-yielding ETF.

Should you invest $1,000 in JPMorgan Equity Premium Income ETF right now?

Before you buy stock in JPMorgan Equity Premium Income ETF, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and JPMorgan Equity Premium Income ETF wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.

See the 10 stocks

*Stock Advisor returns as of April 15, 2024

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. JPMorgan Chase is an advertising partner of The Ascent, a Motley Fool company. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Matt DiLallo has positions in Amazon, JPMorgan Chase, JPMorgan Equity Premium Income ETF, and Meta Platforms. The Motley Fool has positions in and recommends Amazon, JPMorgan Chase, Meta Platforms, and Microsoft. The Motley Fool recommends Progressive and recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.

Abbvie Inc (ABBV-N) Quote - Press Release (2024)

FAQs

What is the AbbVie scandal? ›

CHICAGO – A nationwide class of consumers sued AbbVie, alleging the pharmaceutical company engaged in a fraudulent scheme to inflate the cost of the highest-grossing drug in the world, Humira, by 470% over the last two decades, according to attorneys at Hagens Berman and Carella Byrne Cecchi Brody Agnello.

Did AbbVie buy Allergan for $63 billion? ›

That day, AbbVie officially closed its $63-billion acquisition of Allergan to create a larger, stronger and more diversified global biopharmaceutical company. It was an acquisition that allowed us to grow in numbers and bolster our ability to improve people's lives worldwide.

Is AbbVie still owned by Abbott? ›

AbbVie was founded in 2013 when we became a separate company from Abbott.

Is it a good time to buy AbbVie stock? ›

Based on analyst ratings, AbbVie's 12-month average price target is $185.27. AbbVie has 15.25% upside potential, based on the analysts' average price target. AbbVie has a conensus rating of Strong Buy which is based on 10 buy ratings, 2 hold ratings and 0 sell ratings.

Does Warren Buffett own AbbVie? ›

Buffett owned shares of AbbVie (ABBV -1.23%) in Berkshire's portfolio not too long ago. He subsequently exited his positions in AbbVie and several other big pharma stocks. However, the legendary investor nonetheless still has a stake in AbbVie through NEAM.

Is AbbVie an Israeli company? ›

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois.

Who is the largest shareholder of AbbVie? ›

Top Institutional Holders
HolderSharesDate Reported
Morgan Stanley34.05MDec 31, 2023
Capital Research Global Investors30.3MDec 31, 2023
Charles Schwab Investment Management, Inc.22.72MMar 31, 2024
Northern Trust Corporation20.94MDec 31, 2023
6 more rows

What is AbbVie's biggest selling drug? ›

Abbvie's Humira: a best-seller in the market

Humira is a human monoclonal antibody prescribed to reduce pain and swelling in patients with different types of arthritis like rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis.

Does AbbVie own Botox? ›

BOTOX® and its design are registered trademarks of Allergan, Inc., an AbbVie company. BOTOX® and its design are registered trademarks of Allergan, Inc., an AbbVie company.

What is the old name for AbbVie? ›

In 2011, Abbott announced it was to separate into two leading healthcare companies by the end of 2012. One was to be a diversified medical products company – Abbott – and the other, a new researched-based global biopharmaceutical company – AbbVie. In January 2013, AbbVie was formed.

What is AbbVie's best drug? ›

AbbVie's key product revenues 2022-2023

In 2023, once again, the company's top revenue generating drug was Humira.

Is AbbVie a good company? ›

We've been recognized across the globe as a great place to work. The work we do at AbbVie hasn't gone unnoticed. We've been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 workplace and diversity and inclusion lists.

Why did Buffett sell AbbVie stock? ›

He most likely bought AbbVie because he perceived that it was priced below its intrinsic value and then sold when he believed it was priced above that value. Although Warren Buffett is fond of long-term holdings, such short-term turnarounds are fairly common in classical value investing.

Is ABBV a long-term hold? ›

AbbVie's management has put on a masterclass in executing its transition away from a patent-protected Humira, and it makes the stock a compelling long-term investment idea.

Is AbbVie profitable? ›

Current and historical gross margin, operating margin and net profit margin for AbbVie (ABBV) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. AbbVie net profit margin as of December 31, 2023 is 11.02%.

What are the legal issues with AbbVie? ›

More than a dozen major drug wholesalers are pursuing antitrust claims in federal court in Philadelphia against AbbVie and Besins Healthcare, alleging that AbbVie's Perrigo suit was part of an overarching scheme to beat back competing testosterone gel products.

Is AbbVie a reputable company? ›

We've been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 workplace and diversity and inclusion lists.

What is AbbVie most known for? ›

AbbVie is best known for manufacturing Humira — a medication used to treat moderate-to-severe rheumatoid arthritis and Crohn's disease. AbbVie products include a wide range of drugs.

What is AbbVie best selling drugs? ›

Abbvie's Humira: a best-seller in the market

Humira is a human monoclonal antibody prescribed to reduce pain and swelling in patients with different types of arthritis like rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis.

Top Articles
Latest Posts
Article information

Author: Virgilio Hermann JD

Last Updated:

Views: 6572

Rating: 4 / 5 (41 voted)

Reviews: 88% of readers found this page helpful

Author information

Name: Virgilio Hermann JD

Birthday: 1997-12-21

Address: 6946 Schoen Cove, Sipesshire, MO 55944

Phone: +3763365785260

Job: Accounting Engineer

Hobby: Web surfing, Rafting, Dowsing, Stand-up comedy, Ghost hunting, Swimming, Amateur radio

Introduction: My name is Virgilio Hermann JD, I am a fine, gifted, beautiful, encouraging, kind, talented, zealous person who loves writing and wants to share my knowledge and understanding with you.